Higher risk of cerebral venous thrombosis within one month after the first dose of ChAdOx1 vaccine

Vaccination against the new coronavirus has been carried out quickly and has been very successful in controlling the epidemic
.

Reports of adverse events and clinical case series indicate that the AstraZeneca-Oxford Novel Coronavirus Vaccine (ChAdOx1) is related to the formation of cerebral sinus and venous thrombosis and the occurrence of thrombocytopenia

Vaccination against the new coronavirus has been carried out rapidly and has been very successful in controlling the epidemic

Jörg B.

The team evaluated the incidence of cerebral sinus and venous thrombosis (CVT) and the frequency of vaccine-induced immune thrombotic thrombocytopenia (VITT) within one month after the first vaccination of BNT162b2, ChAdOx1, and mRNA-1273
.

Statistics of CVT cases and other brain disease events within one month after the new coronary pneumonia vaccination

The team evaluated the incidence of cerebral sinus and venous thrombosis (CVT) and the frequency of vaccine-induced immune thrombotic thrombocytopenia (VITT) within one month after the first vaccination of BNT162b2, ChAdOx1, and mRNA-1273

The number of days from the first vaccination of ChAdOx1 to the appearance of neurological symptoms such as CVT and non-CVT events

The number of days from the first vaccination of ChAdOx1 to the appearance of neurological symptoms such as CVT and non-CVT events

The study reported 45 cases of CVT, 9 cases of primary ischemic stroke, 4 cases of primary cerebral hemorrhage, and 4 cases of other neurological events
.

Among CVT patients, 35 cases (77.

The study reported 45 cases of CVT, 9 cases of primary ischemic stroke, 4 cases of primary cerebral hemorrhage, and 4 cases of other neurological events

The incidence of CVT (95% confidence interval) within one month (31 days) after the first SARS-CoV-2 vaccination divided by vaccine type, gender and age group
.

The incidence of CVT (95% confidence interval) within one month (31 days) after the first SARS-CoV-2 vaccination divided by vaccine type, gender and age group
.

For all vaccines, the incidence of CVT within one month after the first dose of 7126434 dose is 0.
55 (95% CI, 0.
38-0.
7 8) per 100,000 people per month (corresponding to the risk of CVT 0.
55 times in the first 31 days) Per 100,000 people per month)
.

For all vaccines, the incidence of CVT within one month after the first dose of 7126434 dose is 0.
55 (95% CI, 0.
38-0.
7 8) per 100,000 people per month (corresponding to the risk of CVT 0.
55 times in the first 31 days) Per 100,000 people per month)
.

For all vaccines, the incidence of CVT within one month after the first dose of 7126434 dose is 0.

ChAdOx1 (after the first dose of 2320535 ChAdOx1) was 1.

In summary, within 31 days of inoculation with ChAdOx1 vaccine, the incidence of cerebral thrombosis is almost 10 times that of mRNA vaccine, and it is more than 3 times that of non-women in women

In short, compared with the mRNA vaccine, the risk of cerebral venous thrombosis inoculated with ChAdOx1 increased by 10 times

Schulz JB, Berlit P, Diener HC, et al.
COVID-19 vaccine-associated cerebral venous thrombosis in Germany [published online ahead of print, 2021 Jul 19].
Ann Neurol.
2021;10.
1002/ana.
26172.
doi:10.
1002/ ana.
26172

Schulz JB, Berlit P, Diener HC, et al.
COVID-19 vaccine-associated cerebral venous thrombosis in Germany [published online ahead of print, 2021 Jul 19].
Ann Neurol.
2021;10.
1002/ana.
26172.
doi:10.
1002/ ana.
26172 Leave a message here